Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1358153 | 0.91 | HTT (0.52) | HTTHPGDSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL12239944 | 0.90 | HTT (0.49) | HTTHPGDSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL12239935 | 0.90 | ALDH1A1 (0.49) | HTTHPGDSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL1842254 | 0.90 | ALDH1A1 (0.51) | HTTHPGDSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL12397455 | 0.89 | ALDH1A1 (0.50) | HTTHPGDSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL12397453 | 0.87 | ALDH1A1 (0.48) | HTTHPGDSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL1357175 | 0.87 | ALDH1A1 (0.48) | HTTHPGDSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL18473879 | 0.83 | HPGD (0.45) | HTTHPGDSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL21120818 | 0.82 | LMNA (0.44) | HPGDALDH1A1LMNAUSP2TSHR | |
| SCHEMBL1358481 | 0.82 | HPGD (0.44) | HTTHPGDSMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3617194-B1 | PROCESSES AND INTERMEDIATES FOR CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS | VIIV HEALTHCARE CO (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20200339565-A1 | PRODRUG SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2020-10-29 | — | — | US | disclosed |
| EP-3617194-A1 | PROCESSES AND INTERMEDIATES FOR CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS | VIIV Healthcare Company (US) | 2020-03-04 | — | — | EP | disclosed |
| EP-2376453-B1 | INTERMEDIATES FOR CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS | VIIV HEALTHCARE CO (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190248785-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2019-08-15 | — | — | US | disclosed |
| US-10335394-B2 | Processes for preparing dolutegravir and cabotegravir and analogues thereof | LEK PHARMACEUTICALS D.D. (SI) | 2019-07-02 | — | — | US | disclosed |
| US-10301321-B2 | Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof | LAURUS LABS LIMITED (IN) | 2019-05-28 | — | — | US | disclosed |
| US-10202379-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | SHIONOGI & CO., LTD. (JP) | 2019-02-12 | — | — | US | disclosed |
| US-20180155364-A1 | NOVEL PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS LIMITED (IN) | 2018-06-07 | — | — | US | disclosed |
| US-20170349587-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| US-20140005405-A1 | PROCESSES AND INTERMEDIATES FOR CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS | VIIV HEALTHCARE COMPANY (US) | 2014-01-02 | — | — | US | disclosed |
| US-8552187-B2 | Processes and intermediates for carbamoylpyridone HIV integrase inhibitors | SHIONOGI & CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-20120184734-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| US-20120022251-A1 | METHOD OF PRODUCING PYRONE AND PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20110282055-A1 | SYNTHESIS OF CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS AND INTERMEDIATES | VIIV HEALTHCARE COMPANY | 2011-11-17 | — | — | US | disclosed |
| US-20110263855-A1 | PROCESSES AND INTERMEDIATES FOR CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS | SHIONOGI & CO., LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2376453-A1 | PROCESSES AND INTERMEDIATES FOR CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS | GlaxoSmithKline LLC (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2376080-A1 | SYNTHESIS OF CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS AND INTERMEDIATES | Shionogi&Co., Ltd. (JP) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010068262-A1 | PROCESSES AND INTERMEDIATES FOR CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010068253-A1 | SYNTHESIS OF CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS AND INTERMEDIATES | SHIONOGI & CO., LTD. (JP) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022251-A1 | METHOD OF PRODUCING PYRONE AND PYRIDONE DERIVATIVES | PNPO, PDXK, CYP3A5 | HTT 3043/4885HPGD 102/4885SMN1; SMN2 4496/4885 |
| US-20120184734-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | CNBP, ZC3HAV1, DPP4 | HTT 3046/4885HPGD 1534/4885SMN1; SMN2 4520/4885 |
| US-10335394-B2 | Processes for preparing dolutegravir and cabotegravir and analogues thereof | SAMHD1, TYMP, DUT | HTT 4725/4885HPGD 1165/4885SMN1; SMN2 3336/4885 |
| US-20190248785-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | HTT 4328/4885HPGD 681/4885SMN1; SMN2 4304/4885 |
| US-20110263855-A1 | PROCESSES AND INTERMEDIATES FOR CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS | INTS6, IDH1, OPRM1 | HTT 3454/4885HPGD 1093/4885SMN1; SMN2 4105/4885 |
| US-10301321-B2 | Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof | CYP3A5, CYP3A43, CYP3A4 | HTT 4537/4885HPGD 706/4885SMN1; SMN2 2638/4885 |
| US-20110282055-A1 | SYNTHESIS OF CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS AND INTERMEDIATES | CDK2, CDK6, BRD4 | HTT 3980/4885HPGD 1839/4885SMN1; SMN2 4684/4885 |
| US-20170349587-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | HTT 4328/4885HPGD 681/4885SMN1; SMN2 4304/4885 |
| US-20180155364-A1 | NOVEL PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CYP3A5, SAMHD1, CYP3A43 | HTT 4668/4885HPGD 1115/4885SMN1; SMN2 3229/4885 |
| US-20200339565-A1 | PRODRUG SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | PREP, UNG, DPP4 | HTT 4361/4885HPGD 599/4885SMN1; SMN2 4365/4885 |
| US-10202379-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | PREP, UNG, DPP4 | HTT 4328/4885HPGD 681/4885SMN1; SMN2 4304/4885 |
| US-20140005405-A1 | PROCESSES AND INTERMEDIATES FOR CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS | INTS6, IDH1, OPRM1 | HTT 3539/4885HPGD 832/4885SMN1; SMN2 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.